2-Isopropyl-4-methyl-1,3,5-triazin | 59101-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2-Isopropyl-4-methyl-1,3,5-triazin
• 英文别名: 2-isopropyl-4-methyl-[1,3,5]triazine；2-Methyl-4-propan-2-yl-1,3,5-triazine
• CAS: 59101-61-0
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: ZXMNVOVWVDTCLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异丁醛 、 乙醛 生成 2-Isopropyl-4-methyl-1,3,5-triazin
  参考文献：
  名称：

  BECKER B. F.; FRITZ H. P., CHEM. BER. , 1976, 109, NO 4, 1346-1352 D2-#5#; #99# #2#4

  摘要：

  DOI：

文献信息

• WDR5 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20200102288A1

  公开（公告）日：2020-04-02

  Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了抑制WDR5和相关蛋白质-蛋白质相互作用的亚氨基-氮杂环-苯甲酰胺化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和状况的方法。
• Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
  申请人：Gaul Michael D.

  公开号：US20090069305A1

  公开（公告）日：2009-03-12

  The present invention relates to substituted nitrogen-containing heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using any of these derivatives and compositions for H 4 receptor activity modulation and the treatment of states mediated by histamine H 4 receptor activity.

  本发明涉及取代的含氮杂芳基衍生物、含有它们的药物组合物，以及使用这些衍生物和组合物中的任一种用于调节H4受体活性和治疗由组胺H4受体活性介导的状态的方法。
• Benzimidazoles useful as inhibitors of protein kinases
  申请人：Binch Hayley

  公开号：US20070099920A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds useful as inhibitors of Aurora, FLT-3, or PDK1 protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the invention.

  本发明涉及作为Aurora、FLT-3或PDK1蛋白激酶抑制剂的化合物。该发明还提供包含这些化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、症状或障碍的方法。该发明还提供了制备本发明化合物的方法。
• [EN] AMINO HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS AMINO HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020157069A1

  公开（公告）日：2020-08-06

  The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory, and autoimmune diseases and cancers.

  本公开涉及式（I）的化合物以及其药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗涉及炎症小体活性的疾病，如炎症性、自身免疫性和自身免疫性疾病以及癌症。
• ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150099738A1

  公开（公告）日：2015-04-09

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, R a , R b , R c , and R d are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式（I）的异噁唑烷FAAH抑制剂或其药学上可接受的形式，其中G、Ra、Rb、Rc和Rd的定义如本文所述。本发明还提供了含有式（I）化合物或其药学上可接受的形式和药学上可接受的载体的制剂。本发明还提供了治疗FAAH介导疾病的方法，包括向需要治疗的受体中投与式（I）化合物或其药学上可接受的形式的治疗有效量。